SAN FRANCISCO, CA — June 19, 2002 —
Orlistat used in conjunction with diet is a valuable adjunctive therapy in overweight and obese type 2 diabetics at all levels of glycemic control, researchers announced at the 62nd Scientific Sessions of the American Diabetes Association (ADA).
Dr. Ralph De Fronzo, from the University of Texas Health Science Center in San Antonio, Texas, United States, presented the results of a retrospective analysis that examined the effect of orlistat on hemoglobin A1c (HbA1c) levels in patients with differing baseline HbA1c levels.
Data were pooled from seven multicenter, double-blind trials in which overweight or obese type 2 diabetics treated with metformin, sulfonylurea, and/or insulin were randomized to treatment with orlistat, 120 mg, or placebo, tid, in addition to a mildly reduced-calorie diet (500 to 600 kcal/d deficit) containing approximately 30 percent of calories as fat, for up to one year. A total of 2,550 patients were randomized to treatment; 1,230 in the placebo group and 1,249 in the orlistat groups were eligible for intent-to-treat analysis.
Results showed that the weight loss from baseline was significantly greater for patients treated with orlistat than for those in the placebo group (-3.8 percent versus 1.4 percent, respectively). The least squares mean (LSM) difference between the two treatment groups was -2.4 kg.
e-Med Tools
קצר קולע וממוקד
e-Med סמינרים
אי-מד תחקירים
Medscape Tools
Journal Club
מרכזי מידע ושירות
Facebook
מידע למפרסם
מאגר תרופות
מאגר אנשי המקצוע
אינדקס שימושי
חדשות משה"ב
eMed HealthClub
מחקרים קליניים
השאירו תגובה
רוצה להצטרף לדיון?תרגישו חופשי לתרום!